Factors influencing circulating microRNAs as biomarkers for liver diseases

Duseja A (2010) Nonalcoholic fatty liver disease in India: a lot done, yet more required! Indian J Gastroenterol 29:217–225 Cheemerla S, Balakrishnan M (2021) Global epidemiology of chronic liver disease. Clin Liver Dis 17(5):365–370 Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18(12):2650–2666 Wang L, Zhang N, Wang Z, Ai DM, Cao ZY, Pan HP (2016) Decreased MiR-155 level in the peripheral blood of non-alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity. Cell Physiol Biochem 39(6):2239–2248 Zhang Y, Cheng X, Lu Z, Wang J, Chen H, Fan W et al (2013) Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract 99(3):327–334 Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO (2016) Association of circulating serum MIR-34a and MIR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS ONE 11(4):1–12 O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:1–12 Pulignani S, Andreassi MG (2019) MicroRNAs and congenital heart disease: where are we now? Rev Esp Cardiol 72(1):7–9 Catalanotto C, Cogoni C, Zardo G (2016) MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci 17:10 Dasgupta I, Chatterjee A (2021) Recent advances in miRNA delivery systems. Methods Protoc 4(1):1–18 Enache LS, Enache EL, Ramière C, Diaz O (2014) Circulating RNA molecules as biomarkers in liver disease 2014:17644–17666 Tang G, Shen X, Lv K, Wu Y, Bi J, Shen Q (2015) Different normalization strategies might cause inconsistent variation in circulating micrornas in patients with hepatocellular carcinoma. Med Sci Monit 21:617–624 Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, Antoine DJ et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5):1767–1776 Bala S, Marcos M, Szabo G, Marcos M (2009) Emerging role of microRNAs in liver diseases. World J Gastroenterol 15(45):5633–5640 Miyaaki H (2014) Significance of serum and hepatic microRNA122 levels in patients with nonalcoholic fatty liver disease. Abstract Background Aims 34(7):2014–2015 Vincent R, Sanyal A (2014) Recent advances in understanding of NASH : microRNAs as both biochemical markers and players. Curr Pathobiol Rep 2:109–116 Armistead D, Estep M, Sharma H, Stepanova M, Birerdinc A, Afendi A et al (2015) Profiling of miRNA in the adipose tissue of the morbidly obese patients with NASH and normal liver biopsies, pp 1–3 Pirola CJ, FernándezGianotti T, Castaño GO, Mallardi P, San Martino J, Ledesma MGL et al (2015) Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64(5):800–812 Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsız G (2014) Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 6(8):613–620 Liu X, Fan Z, Zhao T, Cao W, Zhang L, Li H et al (2015) Plasma MiR-1, MiR-208, MiR-499 as potential predictive biomarkers for acute myocardial infarction: an independent study of Han population. Exp Gerontol 72:230–238 Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C et al (2016) Disease-specific miR-34a as diagnostic marker of nonalcoholic steatohepatitis in a Chinese population. World J Gastroenterol 22(44):9844–9852 Long XR, Zhang YJ, Zhang MY, Chen K, Zheng XFS, Wang HY (2017) Identification of an 88-microRNA signature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases. Aging 9(6):1565–1584 Demerdash HM, Hussien HM, Hassouna E, Arida EA (2017) Detection of MicroRNA in hepatic cirrhosis and hepatocellular carcinoma in hepatitis C genotype-4 in Egyptian patients. Biomed Res Int. https://doi.org/10.1155/2017/1806069 Zhu S, Liu W, Fu B, Yuan Z, Zhou Y, Li H et al (2018) Association of serum miR-205 with liver cirrhosis and cancer and its diagnostic significance. Int J Clin Exp Med 11(11):12375–12380 Fiorino S, Bacchi-Reggiani ML, Visani M, Acquaviva G, Fornelli A, Masetti M et al (2016) MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis b-and c-related-hepatocellularcarcinoma. World J Gastroenterol 22(15):3907–3936 Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D et al (2012) Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 10:151 Köberle V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y et al (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106:1663–1669 Zhang H, Li Q, Guo Z, Guan Y, Du J, Lu Y et al (2012) Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 18(37):5188–5196 Miller AM, Gilchrist DS, Nijjar J, Araldi E, Ramirez CM, Lavery CA et al (2013) MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE 8(8):e72324 Bala S, Szabo G (2012) MicroRNA signature in alcoholic liver disease. Int J Hepatol. 2012:498232 Saikumar J, Ramachandran K, Vaidya VS (2014) Content: summary  Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D et al (2014) Serum MicroRNAs as potential biomarkers of primary biliary cirrhosis. PLoS ONE 9:10 Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70(1):151–171 Roy S, Benz F, Luedde T, Roderburg C (2015) The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr 4(6):24–33 Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS ONE 7:7 Dufourd T, Robil N, Mallet D, Carcenac C, Boulet S, Brishoual S et al (2019) Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers. Biol Methods Protoc 4(1):1–10 Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B et al (2017) Stability of circulating blood-based microRNAs-pre-analytic methodological considerations. PLoS ONE 12(2):1–16 Binderup HG, Madsen JS, Helweg Heegaard NH, Houlind K, Andersen RF, Brasen CL (2018) Quantification of microRNA levels in plasma: impact of preanalytical and analytical conditions. PLoS ONE 13(7):1–13 MaClellan SA, Macaulay C, Lam S, Garnis C (2014) Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol 14(1):1–11 Al-Soud WA, Rådström P (2001) Purification and characterization of PCR-inhibitory components in blood cells. J Clin Microbiol 39(2):485–493 Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C et al (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107(5):677–684 Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M (2014) Methodological challenges in utilizing miRNAs as circulating biomarkers current methodologies for extracting miRNAs from plasma and serum. J Cell Mol Med 18(3):371–390 Kim DJ (2012) Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn 2012:14 Felekkis K, Papaneophytou C (2020) Challenges in using circulating micro-RNAs as biomarkers for cardiovascular diseases. Int J Mol Sci 21:2 Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE et al (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8(1):113–117 Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V (2015) Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int 2015:731479 Garzon R, Croce CM (2008) MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15(4):352–358 Reddy LL, Shah SAV, Ponde CK, Rajani RM, Ashavaid TF (2019) Circulating miRNA-33: a potential biomarker in patients with coronary artery disease. Biomarkers 24(1):36–42 Mitchell AJ, Gray WD, Hayek SS, Ko YA, Thomas S, Rooney K et al (2016) Platelets confound the measurement of extracellular miRNA in archived plasma. Sci Rep 6:1–11 McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57(6):833–840 Mitchell PS (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513 Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL et al (2014) Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cell Biochem 115(5):805–811 Zhao H, Shen J, Hu Q, Davis W, Medico L, Wang D et al (2014) Effects of preanalytic variables on circulating microRNAs in whole blood. Cancer Epidemiol biomarkers Prev 23(12):2643–2648 Cacheux J, Bancaud A, Leichlé T, Cordelier P (2019) Technological challenges and future issues for the detection of circulating micrornas in patients with cancer. Front Chem 2019:7 Ag S, Schöler N, Bommer M, Jh N, Tumani H, Rouhi A et al (2015) Impact of serum storage conditions on microRNA stability. Leukemia 26:2414 Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Piiper A et al (2015) Serum microRNA1 and microRNA122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49:3442 Zhang Z (2011) MicroRNA degradation and turnover: regulating the regulators. Bone 23(1):1–7 Pös O, Biró O, Szemes T, Nagy B (2018) Circulating cell-free nucleic acids: characteristics and applications. Eur J Hum Genet 26(7):937–945 El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G (2016) Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep 6(1):19529 Gautam A, Kumar R, Dimitrov G, Hoke A, Hammamieh R, Jett M (2016) Identification of extracellular miRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple methods. Mol Biol Rep 43(10):1165–1178 Rice J, Roberts H, Burton J, Pan J, States V, Rai SN et al (2015) Assay reproducibility in clinical studies of plasma miRNA. PLoS ONE 10(4):1–23 El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G (2016) Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep 6:1–14 Garcia-Elias A, Alloza L, Puigdecanet E, Nonell L, Tajes M, Curado J et al (2017) Defining quantification methods and optimizing protocols for microarray hybridization of circulating microRNAs. Sci Rep 7(1):1–14 Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13(5):358–369 Bernardo B, Charchar F, Lin R, Mcmullen J (2011) A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ 7(21):131–142 Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D et al (2010) Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16(11):2170–2180 Tchernitsa O, Kasajima A, Schäfer R, Kuban RJ, Ungethüm U, Györffy B et al (2010) Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 222(3):310–319 Lamba V, Ghodke-Puranik Y, Guan W, Lamba JK (2014) Identification of suitable reference genes for hepatic microRNA quantitation. BMC Res Notes 7:1 De Ronde MWJ, Ruijter JM, Moerland PD, Creemers EE, Pinto-Sietsma SJ (2018) Study design and qPCR data analysis guidelines for reliable circulating miRNA biomarker experiments: a review. Clin Chem 64(9):1308–1318 Li Y, Xiang GM, Liu LL, Liu C, Liu F, Jiang DN et al (2015) Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. Mol Med Rep 12(3):4683–4691 Schwarzenbach H, Silva A, Calin G, Pantel K (2015) Data normalization strategies for microRNA quantification. Clin Chem 26:61 Mehta R, Otgonsuren M, Younoszai Z, Allawi H, Raybuck B, Younossi Z (2016) Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol 3(1):1–7 Ye D, Zhang T, Lou G, Xu W, Dong F, Chen G et al (2018) Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci 208:201–207 Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M et al (2015) Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS ONE 10(11):1–11 Marabita F, de Candia P, Torri A, Tegnér J, Abrignani S, Rossi RL (2016) Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 17(2):204–212 Kok MGM, Halliani A, Moerland PD, Meijers JCM, Creemers EE, Pinto-Sietsma S-J (2015) Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. FASEB J 29(9):3853–3862 Lou W, Liu J, Ding B, Chen D, Xu L, Ding J et al (2019) Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0604 Genetics. J Transl Med 17(1):1–14 Wang X, Zhang X, Yuan J, Wu J, Deng X, Peng J et al (2018) Evaluation of the performance of serum miRNAs as normalizers in microRNA studies focused on cardiovascular disease. J Thorac Dis 10(5):2599–2607 Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R (2019) Serum microRNAs as biomarkers in hepatitis C: preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma. Int J Mol Sci 20(4):1–13 Krauskopf J, Caiment F, Claessen SM, Johnson KJ, Warner RL, Schomaker SJ et al (2015) Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci 143(2):268–276 Li Y, Jiang Z, Xu L, Yao H, Guo J, Ding X (2011) Stability analysis of liver cancer-related microRNAs. Acta Biochem Biophys Sin 43(1):69–78 Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S et al (2016) Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer 138(11):2732–2744 Tan Y, Ge G, Pan T, Wen D, Gan J (2014) A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS ONE 9(8):105192 López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza Á, Perez-Rojas J et al (2018) Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep 8(1):1–15 Yao S (2016) MicroRNA biogenesis and their functions in regulating stem cell potency and differentiation. Biol Proc 18(1):1–10 Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S (2018) Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). MicroRNA 7(3):215–222 Lai M, Yang Z, Zhou L, Zhu Q, Xie H, Zhang F et al (2012) Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 29(3):1810–1816 Madadi S, Schwarzenbach H, Lorenzen J, Soleimani M (2019) MicroRNA expression studies: challenge of selecting reliable reference controls for data normalization. Cell Mol Life Sci 76(18):3497–3514 Ezzat H, Lotfy AM, Alalfy MN, Salwa ME (2014) The significance of circulating micro RNA-122 as a non invasive diagnostic marker of liver injury in Egyptian chronic hepatitis C virus infected and cirrhotic patients with and without hepatocellular carcinoma. Clin Med Diagnostics 4(1):1–8 Soronen J, Yki-Järvinen H, Zhou Y, Sädevirta S, Sarin AP, Leivonen M et al (2016) Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep 4(1):1–14 Ryu JK, Hong S-M, Karikari CA, Hruban RH, Goggins MG, Maitra A (2010) Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10(1):66–73 Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K et al (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424:99–103 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 6(8):2–9 Li Y, Zhang L, Liu F, Xiang G, Jiang D, Pu X (2015) Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma. Dis Mark 2015:893594 Kang K, Peng X, Luo J, Gou D (2012) Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. J Anim Sci Biotechnol. 3(1):4 Bellan M, Castello LM, Pirisi M (2018) Candidate biomarkers of liver fibrosis: a concise, pathophysiology-oriented review. J Clin Transl Hepatol 6(3):1–9 Li J, Chen H, Ren J, Song J, Zhang F, Zhang J et al (2015) Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina. BMC Med Genom 8:12 Nguyen TH, Liu X, Su ZZ, Hsu AC-Y, Foster PS, Yang M (2018) Potential role of MicroRNAs in the regulation of antiviral responses to influenza infection. Front Immunol 9:1541 Landrier J-F, Derghal A, Mounien L (2019) MicroRNAs in obesity and related metabolic disorders. Cells 8(8):859 Beckett EL, Yates Z, Veysey M, Duesing K, Lucock M (2014) The role of vitamins and minerals in modulating the expression of microRNA. Nutr Res Rev 27(1):94–106 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT (2020) Evolution of NAFLD and its management. Nutr Clin Pract 35(1):72–84 Ross SA, Davis CD (2014) The emerging role of microRNAs and nutrition in modulating health and disease. Annu Rev Nutr 34:305–336 Bennet L, Johansson S-E, Agardh C-D, Groop L, Sundquist J, Råstam L et al (2011) High prevalence of type 2 diabetes in Iraqi and Swedish residents in a deprived Swedish neighbourhood: a population based study. BMC Public Health 11:303 Wang X, Sundquist J, Zöller B, Memon AA, Palmér K, Sundquist K et al (2014) Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 9(1):e86792 Bovell LC, Shanmugam C, Putcha B-DK, Katkoori VR, Zhang B, Bae S et al (2013) The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 19(14):3955–3965 Dluzen DF, Noren Hooten N, Zhang Y, Kim Y, Glover FE, Tajuddin SM et al (2016) Racial differences in microRNA and gene expression in hypertensive women. Sci Rep 6:35815 Rawlings-Goss RA, Campbell MC, Tishkoff SA (2014) Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genom 7:53 Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S (2015) Circulating miRNA profile in HCV infected serum : novel insight into pathogenesis. Sci Rep 3:1555 Singh AK, Rooge SB, Varshney A, Vasudevan M, Bhardwaj A, Venugopal SK et al (2018) Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury. Hepatology 67(5):1695–1709 Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P (2019) Expression analysis of microRNA-21 and microRNA-122 in hepatocellular carcinoma. J Clin Exp Hepatol 9(3):294–301 Nayak B, Nadda N, Paul S, Shalimar ASK, Saraya A (2017) To study changes in circulatory microrna expression in hepatocellular carcinoma patients receiving locoregional therapy and its correlation with therapeutic response. J Clin Exp Hepatol 7:81 Biju BM, Chhabra SS, Sarkar C (2020) Elucidation of novel miRNA candidates and their role in unraveling the pathology of nonalcoholic fatty liver disease. bioRxiv Ono S, Lam S, Nagahara M, Hoon DSB (2015) Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays. J Clin Med 4(10):1890–1907 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H et al (2016) Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 10(4):647–656 Jin BX, Zhang YH, Jin WJ, Sun XY, Qiao GF, Wei YY et al (2015) MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep 5:15026 Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Diego S, Jolla L et al (2016) HHS Public Access 65(9):1546–1554 Auguet T, Aragonès G, Berlanga A, Guiu-Jurado E, Martí A, Martínez S et al (2016) miR33a/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease. Int J Mol Sci 17(10):1–17 López-Riera M, Conde I, Tolosa L, Zaragoza Á, Castell JV, Gómez-Lechón MJ et al (2017) New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease. Front Pharmacol 8:1–12 Jaeger A, Zollinger L, Saely CH, Muendlein A, Evangelakos I, Nasias D et al (2018) Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. Sci Rep 8(1):1–14 Zhang J, Ma J, Wang H, Guo L, Li J (2017) Serum microRNA-30c levels are correlated with disease progression in xinjiang uygur patients with chronic hepatitis B. Brazil J Med Biol Res 50(6):1–7 Wang T, Lin D, Jin B, Sun X, Li N (2018) Plasma microRNA: a novel non-invasive biomarker for HBV-associated liver fibrosis staging. Exp Ther Med 17:1919–1929 Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH et al (2019) Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep 9(1):1–12 Lambrecht J, Poortmans PJ, Verhulst S, Reynaert H, Mannaerts I, van Grunsven LA (2017) Circulating ECV-associated miRNAs as potential clinical biomarkers in early stage HBV and HCV induced liver fibrosis. Front Pharmacol 8:1–13 Meng J, Zhang D, Pan N, Sun N, Wang Q (2015) Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis. Peer J 3:1–15 Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S (2013) Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 3:1–7 Chen Y, Zhu J, Wu H, Fan J, Zhou J, Hu J et al (2013) Circulating microRNAs as a fingerprint for liver cirrhosis. PLoS ONE 8(6):1–9 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T et al (2016) Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Eur J Cancer 61(33):154 Fibrosis L, Lambrecht J, Verhulst S, Reynaert H (2019) Scoring algorithm for the diagnosis of significant Starlinger P, Hackl H, Pereyra D, Skalicky S, Geiger E, Finsterbusch M et al (2019) Predicting postoperative liver dysfunction based on blood-derived microRNA signatures. Hepatology 69(6):2636–2651 Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165(5):305–315 Huang YH, Liang KH, Chien RN, Hu TH, Lin KH, Hsu CW et al (2017) A circulating MicroRNA signature capable of assessing the risk of hepatocellular carcinoma in cirrhotic patients. Sci Rep 7(1):1–12 Bai X, Liu Z, Shao X, Wang D, Dong E, Wang Y et al (2019) The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma. PLoS ONE 14(2):1–15 Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H et al (2014) Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 34(7):1–6